a1-AT, a1-antitrypsin; PCR, polymerase chain reaction; ASO, allele-specific oligonucleotide; and ARMS, Amplification Refractory Mutation System.
a1-AT deficiency results
System (ARMS) (12), and PCR combined with cleavage by RNase A (13) . All of these assays have shortcomings for use in routine diagnosis. They are too laborious, involve the use of radioactivity, or are unreliable.
To overcome these shortcomings, we have designed two new nonradioactive PCR-based assays to detect Z and S mutations in the a1-AT gene.
The new assays are based on the principle of using We previously used this technique to detect the most frequent mutation in the medium-chain acyl-CoA dehydrogenase gene (15, 16) and to detect the apoBlOO 3500 mutation in the gene for apolipoprotein B100 (17) . Here we compare the new assays with the conventional ASO-probe assays for the Z and S mutations by typing purified genomic DNA from patients with diagnosed a1-AT deficiency, from patients with pulmonary emphysema, and from a family whose members exhibit both the Z and S mutations.
We also show that the new assays can be performed directly with boiled blood spots, making diagnosis fast and easy. Finally, we report use of the new assays for prenatal diagnosis of two cases of a1-AT deficiency in the same family, and show that the new assays can also be performed directly with boiled samples of chorionic villus tissue. oil. The details of the various PCR amplifications are described in Table 1 .
Materials and Methods

Materials
A blank amplification containing all reagents but no sample DNA was always included in the experiments to check for the presence of contaminating DNA from cloned or previously amplified DNA.
PCR combined with ASO probe analysis for the Z and S mutations.
A 148-bp fragment containing the region harboring the site for the S mutation and a 139-bp fragment harboring the Z mutation site were co-amplified in one PCR procedure with use of the four oligonucleotide primers p1, p2, p3, and p4 (Table 2) Table 2 ). After hybridization, the membranes were washed separately at low stringency, followed by stringent washing at temperatures specific for each probe. The bound probes were made visible by autoradiography.
Details of the ASO probe analysis for the S and Z mutations in PCRamplified DNA were described previously (9,18).
PCR amplification mutagenesis and diagnostic restriction enzyme digestion for the Z and S mutations. The principles of the new assays are described in Figure 1 . For convenience we optimized both assays so that the 
S mutation primers
5'-CAATGCCACCGCCATCTrCTrCCTGCCTG-3'
5'-GAACTFGACCTCGAGGGGGATAGAC-3'
ASO probes for the S mutation site
ASO probes for the Z mutation site ZM
5'-ACCATCGACGAGAAAGGGACT-3' Z 5'-ACCATCGACAAGAAAGGGACT-3'
Nucleotides corresponding to the mutation site are underlined.
amplifications could be performed with the same PCR program. Thus, the two assays can be performed simultaneously, making diagnosis for the two mutations easier.
In the S mutation assay, the p7702 primer ( Upper pane!: In the S mutation assay, PCR amplification with the two primers p7553 and p7702 produces a 149-bp fragment of axon Illof the a1-AT gene. The p7702 primerIntroduces a diagnostic Xmnl she (GAANNNNTI'C)only in the PCR product from normal alleles but not In that from alleles bearing the S mutation.
The presence or absence of this Xmnl site makes Itpossible to distinguish between PCR-ampllfled normaland S mutation-bearing alleles after cleavagewithXmnl followed by polyacrylammdegel electrophoresis. The p7553primer introduces a Xrnnl site In all amplification products; therefore, thIs site serves as an Internal control for the restrictionenzymecleavage. Aftercleavage with Xmnl, amplified S mutation-bearing alleles are 133 bp and amplIfied normal alleles are 111 bp.
Lower pane!: Inthe Z mutation assay, PCR amplification with the two primers p9966 and p10063 produces a 97-bp fragment of exon Vol the a1-AT gene. The p9966 prImer Introduces a Taql sIte (TCGA) only mnthe PCR product from normal alleles but not Inthat from alleles beating the Z mutation. The presence or absence of this Taql site makes Itpossible to distinguish between normal and Z mutation-bearing alleles after cleavage with TaqI followed by polyactylamlde gel electrophoresls. The p10063 primer introduces a Taql site in all PCR products; therefore, this Taql site serves as an internalcontrol for restriction enzyme cleavage. After cleavage with Taql, amplified Z mutation-bearing alleles are 86 bp and amplified normal alleles are 64 bp we used both methods to test purified genomic DNA from family I. The results of the typing for the S mutation (Figure 2 ) and the Z mutation (Figure 3) Figure 4 ) with the results obtained by the new methods for assays of blood spots (Figure 4) shows that the diagnoses totally agree. Moreover, the results obtained when the two new assays are performed with blood spots (Figure 4 ) are just as easy to interpret as the results obtained by the new assays performed with purified genomic DNA from members of family I (Figures 2 and 3) .
#{149}
M/M M/Z S/S Z/Z M/S MIZ S/Z M/Z S/Z MIS MIZ
Purified genomic DNA samples (in some cases also blood spots) from 16 patients with a clinical history of pulmonary emphysema and from 8 patients with diagnosed a1-AT deficiency were tested with the new assays.
The results were compared with results obtained previously (18, and unpublished results) , when genomic DNA samples from the same patients were tested with the traditional PCRJASO probe assays. In all cases, the results obtained with the two new assays were in complete accordance with the results obtained previously. The age of the blood spots or of the frozen blood did not seem to influence the performance of the two assays.
After having confirmed the good performances of the new assays, we used them for prenatal diagnoses. Family III had previously had a seriously affected child, who is homozygous for the Z mutation. By testing purified genomic DNA from the parents and the index patient, we confirmed the previous diagnosis (obtained by the PCR/ASO probe assay), showing that the parents are heterozygous carriers (Figure 51, lanes 1 and 2) and that the index patient is homozygous for the Z mutation (Figure 51, lane 3) . The first prenatal diagnosis was performed with purified genomic DNA from chorionic villus biopsies obtained from each of two dizygotic twin fetuses. In the Z mutation assay, the DNA from both fetuses displayed a single band at 86 bp (Figure 51, lanes  4 and 5) , showing that both samples were homozygous for the Z mutation. On this basis, the parents chose to abort the twin fetuses. After termination of the pregnancy, the diagnosis was verified in DNA samples from cultured cells of the aborted fetuses (Figure 5t, lanes F1  and F2) (Figure 51!, lane CVD) . Because only the 64-bp band was observed in all the fetal samples, we concluded that this fetus was homozygous for the normal allele and the pregnancy was continued. all samples tested (results not shown) . Therefore, we concluded that all samples were normal with respect to this site.
DiscussIon
Diagnosis of a1-AT deficiency has traditionally been based on isoelectric focusing and measurement of the a1-AT protein concentration in serum. This method is fast and simple, but interpretation of the banding pattern obtained by isoelectric focusing is difficult and requires specially trained personnel. Alternative methods of diagnosis involve determination of the diseasecausing mutations in DNA samples by PCR-based assays (9) (10) (11) (12) (13) . The most widely used techniques for this are PCR combined with ASO probes and the ARMS assay.
PCR combined with ASO probes for the Z and S mutations (9) The use of blood spots is also desirable because they are easier to ship and store than are blood samples.
In our experience, the most critical step in the new assays is the restriction enzyme digestion step. Therefore, when constructing the assay, great care should be taken to ensure that the preconditions for complete digestion are as good as possible-avoiding production of primer-dimer product in the PCR, and choosing the optimal restriction enzyme site to create without limiting whether the restriction enzyme site should be created in the mutant sequence or in the normal sequence (21) .
Another very important element that is often ignored (22) (23) (24) (25) is inclusion of control sites for restriction enzyme cleavage. Including a control site will indicate when digestion is incomplete, thereby avoiding problems with false-negative or false-positive results.
The control sites in our assays are placed in such a way that the cleaved-off fragments are a different size (16 bp in the S assay and 11 bp in the Z assay) from the fragment cleaved off at the mutation site (22 bp in both the S and Z assays). Given this difference in fragment sizes, we can distinguish unambiguously between cases of incomplete digestion and true heterozygosity.
In contrast to
the problems we encountered in optimizing the restriction enzyme digestion step, the PCR amplification step was less difficult to optimize. Even when one of the primers contained a mismatch as close as at position 2 from the 3'-terminus (p9966 primer in the Z mutation assay) or had as many as three mismatching nucleotides located in the middle (p7553 primer in the S mutation assay), successful amplification was easy to attain. Because PCR can tolerate rather drastic mismatching, we believe it would be easy to manipulate the sequences around any given mutation site by PCRbased mutagenesis in such a way that the sequences can be recognized and discriminated by restriction enzymes.
This belief has thus far been corroborated by the fact that the method has been used to detect mutations in the genes for -globin (21) 
